Target: GFAP
Conjugate: HRP
Product Type: Monoclonal
Clone Number: N206B/9 (Formerly sold as S206B-9)
Immunogen: Synthetic peptide amino acids 411-422 (KTVEMRDGEVIK) of human GFAP; 100% identical in rat and mouse. >50% identity with other proteins (Vimentin, Desmin and Peripherin).
Swiss-Prot: P14136
Purification: Protein G Purified
Storage Buffer: 73.64mM Carbonate, 54.55mM Ethanolamine, 45.45mM Cyanoborohydride, 18.18mM Sodium Hydroxide and 0.23mM Citrate in dH2O
Concentration: 1 mg/ml
Specificity: Detects ~50kDa. Does not cross-react with GFAP-R416W or other proteins (based on KO validation results).
Cellular Localization: Cytoplasm
Scientific Background: The 50 kDa type III intermediate filament protein glial fibrillary acidic protein (GFAP) is a major structural component of astrocytes. GFAP associates with the calcium binding protein annexin II-p2 and S-100. Association with these proteins together with phosphorylation regulates GFAP polymerization. Astroycytes respond to brain injury by proliferatin (astrogliosis), and one of the first events to occur during astrocyte proiliferation is increased GFAP expression. Interestingly, antibodies to GFAP have been detected in individuals with dementia.
References: 1. Velasco M.E., et al. (1980) Cancer. 45:484.2. Bonnin J.M., et al. (1984) Acta Neuropathology. 62:185.3. Lee VM-Y., et al. (1984) J. Neurochem. 42:25-32 (1984).4. Trojanowski JQ et al. (1986) J. Neurochem. 6(3): 650-660 (1986).5. Schmidt ML et al; Lab Invest 56:282-294 (1987).6. Kosik KS et al; Neuron 1:817-825 (1988).7. Schmidt ML et al; Lab Invest 59:460-466 (1988).8. Mokuna, K, et al: J Neurosci Res 23:396 (1989).9. Molenaar, et al; Exp Neurology 108:1-9 (1990).10. Tohyama T et al; Am J Pathol, 142:871-882 (1993).11. Tohyama T et al; Am J Pathol 142:883-892 (1993).12. Thilenius, A.R.B., et al; J. Immunol. 162(2): 643-650 (1999).
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
